非小细胞肺癌患者临床试验中靶向治疗、免疫治疗与化疗的停药时间分析
研究分析了2007年后提交美国食品药品监督管理局的18项转移性非小细胞肺癌随机临床试验,共8947例患者,评估停药时间(TTD)与无进展生存期(PFS)和总生存期(OS)的关联。结果显示TTD与PFS的关联(r=0.87)强于与OS的关联(r=0.68)。在EGFR突变阳性和ALK阳性患者中,中位TTD超过中位PFS。作者认为TTD可作为持续给药疗法的实用随机真实世界证据试验的终点,需前瞻性进一步研究。
要点
- 在8947例转移性非小细胞肺癌患者中,TTD与PFS的关联(r=0.87,95%CI 0.86-0.87)强于与OS的关联(r=0.68,95%CI 0.67-0.69)。
- 早期TTD(PFS-TTD≥3个月)总体发生率为7.7%,化疗单药组更常见(15.0%);晚期TTD(TTD-PFS≥3个月)总体为6.0%,EGFR阳性和ALK阳性组更常见(分别为12.4%和22.9%)。
- 在EGFR阳性和ALK阳性亚组中,中位TTD(13.4和14.1个月)超过中位PFS(11.4和11.3个月)。
核心结论
- 在患者层面,TTD与PFS的关联跨越不同治疗类别。
- 对于接受致癌基因靶向治疗的生物标志物选择患者,中位TTD超过中位PFS。
- TTD应仅针对持续给药疗法,作为实用随机真实世界证据试验的终点进行前瞻性进一步研究。
研究设计与样本
- 研究分析了2007年后提交美国食品药品监督管理局的18项转移性非小细胞肺癌随机临床试验,共8947例患者。
- TTD计算为从随机化日期到停药或死亡日期,并与PFS和OS在所有患者及治疗定义亚组中进行比较。
- 治疗定义亚组包括:EGFR突变阳性接受酪氨酸激酶抑制剂(TKI)治疗、EGFR野生型接受TKI治疗、ALK阳性接受TKI治疗、免疫检查点抑制剂(ICI)、化疗双药联合维持治疗、化疗单药治疗。
主要发现
- 总体8947例患者中,TTD与PFS的关联(r=0.87,95%CI 0.86-0.87)比与OS的关联(r=0.68,95%CI 0.67-0.69)更密切。
- 早期TTD(PFS-TTD≥3个月)总体发生率为7.7%,化疗单药组更常见(15.0%)。
- 晚期TTD(TTD-PFS≥3个月)总体发生率为6.0%,EGFR阳性和ALK阳性患者更常见(分别为12.4%和22.9%)。
- 在致癌基因靶向亚组(EGFR阳性和ALK阳性)中,中位TTD(13.4和14.1个月)超过中位PFS(11.4和11.3个月)。
临床怎么用
- 作者认为,TTD应仅针对持续给药疗法,作为实用随机真实世界证据试验的终点进行前瞻性进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pragmatic end points, such as time-to-treatment discontinuation (TTD), defined as the date of starting a medication to the date of treatment discontinuation or death has been proposed as a potential efficacy end point for real-world evidence (RWE) trials, where imaging evaluation is less structured and standardized. PATIENTS AND METHODS: We studied 18 randomized clinical trials of patients with metastatic non-small-cell lung cancer (mNSCLC), initiated after 2007 and submitted to U.S. Food and Drug Administration. TTD was calculated as date of randomization to date of discontinuation or death and compared to progression-free survival (PFS) and overall survival (OS) across all patients, as well as in treatment-defined subgroups [EGFR mutation-positive treated with tyrosine kinase inhibitor (TKI), EGFR wild-type treated with TKI, ALK-positive treated with TKI, immune checkpoint inhibitor (ICI), chemotherapy doublet with maintenance, chemotherapy monotherapy]. RESULTS: Overall across 8947 patients, TTD was more closely associated with PFS (r = 0.87, 95% CI 0.86-0.87) than with OS (0.68, 95% CI 0.67-0.69). Early TTD (PFS-TTD ≥ 3 months) occurred in 7.7% of patients overall, and was more common with chemo monotherapy (15.0%) while late TTD (TTD-PFS ≥ 3 months) occurred in 6.0% of patients overall, and was more common in EGFR-positive and ALK-positive patients (12.4% and 22.9%). In oncogene-targeted subgroups (EGFR positive and ALK positive), median TTDs (13.4 and 14.1 months) exceeded median PFS (11.4 and 11.3 months). CONCLUSIONS: At the patient level, TTD is associated with PFS across therapeutic classes. Median TTD exceeds median PFS for biomarker-selected patients receiving oncogene-targeted therapies. TTD should be prospectively studied further as an end point for pragmatic randomized RWE trials only for continuously administered therapies.
引用
- Blumenthal GM, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019. PMID: 30796424. doi:10.1093/annonc/mdz060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。